We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
Read MoreHide Full Article
Shares of BioSpecifics Technologies Corp. have increased 77.6% in the past year, against the industry’s decline of 16.1%.
In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missed in one, with the average earnings surprise being 17.04%.
Let’s see how things are shaping up prior to the announcement of the upcoming fourth-quarter and full-year 2018 results.
Factors Likely to Impact Q4 Results
BioSpecifics develops collagenase-based therapies, with a first-in-class collagenase-based product marketed a Xiaflex in the United States and Xiapex in Europe.
The company is witnessing continued growth for the two marketed indications for Xiaflex — Peyronie's Disease and Dupuytren's Contracture. We expect this positive trend to continue in the fourth quarter.
BioSpecificsannounced positive data for Xiaflex [collagenase clostridium histolyticum (CCH)] in two new potential indications in the fourth quarter. The company announced positive top-line results from its phase I study of CCH for the treatment of uterine fibroids in October 2018. Also, BioSpecifics’ partner, Endo International Plc. announced positive data from the phase III studies of CCH for the treatment of cellulite in November 2018.
BioSpecifics is taking care of CCH’sdevelopment in the uterine fibroids indication and has the right to initiate the development of any new potential indication not licensed by Endo.
Investors’ focus will be on pipeline updates in the fourth quarter.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for BioSpecifics in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: BioSpecifics has an Earnings ESP of 0.0% as both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a profit of 68 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: BioSpecifics currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
BioSpecifics Technologies Corp Price and EPS Surprise
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
BioDelivery Sciences International Inc. is scheduled to report fourth-quarter results on Mar 14. The company has an Earnings ESP of +38.46% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Tilray Inc. (TLRY - Free Report) is expected to report fourth-quarter results on Mar 18. The company has an Earnings ESP of +7.41% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases.
They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in Store for BioSpecifics (BSTC) This Earnings Season?
Shares of BioSpecifics Technologies Corp. have increased 77.6% in the past year, against the industry’s decline of 16.1%.
In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missed in one, with the average earnings surprise being 17.04%.
Let’s see how things are shaping up prior to the announcement of the upcoming fourth-quarter and full-year 2018 results.
Factors Likely to Impact Q4 Results
BioSpecifics develops collagenase-based therapies, with a first-in-class collagenase-based product marketed a Xiaflex in the United States and Xiapex in Europe.
The company is witnessing continued growth for the two marketed indications for Xiaflex — Peyronie's Disease and Dupuytren's Contracture. We expect this positive trend to continue in the fourth quarter.
BioSpecificsannounced positive data for Xiaflex [collagenase clostridium histolyticum (CCH)] in two new potential indications in the fourth quarter. The company announced positive top-line results from its phase I study of CCH for the treatment of uterine fibroids in October 2018. Also, BioSpecifics’ partner, Endo International Plc. announced positive data from the phase III studies of CCH for the treatment of cellulite in November 2018.
BioSpecifics is taking care of CCH’sdevelopment in the uterine fibroids indication and has the right to initiate the development of any new potential indication not licensed by Endo.
Investors’ focus will be on pipeline updates in the fourth quarter.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for BioSpecifics in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: BioSpecifics has an Earnings ESP of 0.0% as both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a profit of 68 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: BioSpecifics currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
BioSpecifics Technologies Corp Price and EPS Surprise
BioSpecifics Technologies Corp Price and EPS Surprise | BioSpecifics Technologies Corp Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
BioDelivery Sciences International Inc. is scheduled to report fourth-quarter results on Mar 14. The company has an Earnings ESP of +38.46% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Tilray Inc. (TLRY - Free Report) is expected to report fourth-quarter results on Mar 18. The company has an Earnings ESP of +7.41% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases.
They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>